SAUGERTIES, NY (January 28, 2011) — HITS, Inc. is pleased to announce that Luitpold Pharmaceuticals, Inc., manufacturers of Adequan (polysulfated glycosaminoglycan), the only FDA-approved disease modifying osteoarthritic drug treatment for equine non-infectious degenerative joint disease, will once again sponsor the popular Adequan Hunter Division at all HITS horse shows nationwide.
Luitpold Animal Health believes that the demands on show horses, particularly at the top performance level, require attention to details and a solid plan for maintaining soundness.
Adequan i.m. is the flagship equine product from Luitpold Pharmaceuticals, Inc. Unlike corticosteroids and non-steroidal anti-inflammatory drugs, which only ease the source of pain and decrease inflammation of the synovial membrane, Adequan i.m. breaks the destructive disease cycle associated with osteoarthritis. It helps to restore the natural cycle of “wear and repair” within a joint and blocks the enzymes that damage joints and restores synovial lubrication within the joint. The treatment regime of 1 intramuscular injection every 4 days for 7 treatments protects cartilage structure, inhibits cartilage damage and stimulates the natural cartilage repair process. It also decreases inflammation and relieves the pain associated with DJD.
